Rosuvastatin
Rosuvastatin
Definition
A statin with antilipidemic and potential antineoplastic activities. Rosuvastatin selectively and competitively binds to and inhibits hepatic hydroxymethyl-glutaryl coenzyme A (HMG-CoA) reductase, the enzyme which catalyzes the conversion of HMG-CoA to mevalonate, a precursor of cholesterol. This leads to a decrease in hepatic cholesterol levels and increase in uptake of LDL cholesterol. In addition, rosuvastatin, like other statins, exhibits pro-apoptotic, growth inhibitory, and pro-differentiation activities in a variety of tumor cell types; these antineoplastic activities may be due, in part, to inhibition of the isoprenylation of Ras and Rho GTPases and related signaling cascades.
Also known as ROSUVASTATIN — per NCIT
Also identified as
- ATC C10AA07 per RXNORM
- NCIT NCIT:C66523 per NCIT
- SCTID 700067006 per RXNORM
- SCTID 768151007 per RXNORM
- UNII 413KH5ZJ73 per RXNORM
Indications
| Disease | Relation | Source |
|---|---|---|
| Coronary artery disorder | may prevent | MEDRT · Public domain (U.S. Government work) |
| Coronary artery disorder | may treat | MEDRT · Public domain (U.S. Government work) |
| Hyperlipoproteinemia | may treat | MEDRT · Public domain (U.S. Government work) |
| Hypertriglyceridemia | may treat | MEDRT · Public domain (U.S. Government work) |
Organ Effects
| Organ | Side effect / interaction | Source |
|---|---|---|
| Cardiovascular system | may treat a disease of this organ | DERIVED · CC BY 4.0 |
| Heart | may treat a disease of this organ | DERIVED · CC BY 4.0 |
2 entries above are marked DERIVED: Atlas Médico inferred them by combining two sourced claims, and no source asserts these links directly. Treat them as a navigation aid, not as a clinical statement.